CRYM protein counteracts the expansion of prostate tumors

Prostate cancer is caused by increased hormone levels, and tumors are generally treated with hormone therapy. However, after a while, tumor growth is no longer dependent on hormones, resulting in resistance to treatment. As a result, new types of treatments are urgently needed.

A research team led by Lukas Kenner from the Department of Pathology at MedUni Vienna in collaboration with David Heery from the University of Nottingham / UK and Sarka Pospisilova and Suzanne Turner from the University of Brno / Czech Republic has shown that the protein μ-crystalline ( CRYM) plays an important role in tumor growth. Their results were based on the genetic analysis of numerous tissue samples. The higher the levels of this protein present, the better the prognosis. The study was published in the International Journal of Cancer, a leading journal.

Prostate cancer is one of the most frequently diagnosed types of cancer in men and affects around 5,600 men in Austria every year. Hormone therapy is one of the core treatment strategies, but it is only effective for a limited period of time. It has been known for some time that the thyroid hormone T3 may play a role in the development of prostate tumors, but until now the question of how it does this has remained unanswered.

A research team led by Lukas Kenner from the Department of Pathology at MedUni Vienna in collaboration with David Heery from the University of Nottingham / UK and Sarka Pospisilova and Suzanne Turner from the University of Brno / Czech Republic has now shown that the protein CRYM binds the hormone T3 and inhibits tumor growth. The results were based on an analysis of protein molecules in tissue sections and genetic data from hundreds of prostate cancer patients.

The main author Lukas Kenner, member of the Comprehensive Cancer Center established by MedUni Vienna and the Vienna General Hospital (AKH): "Our work shows that CRYM is a key regulator of T3 metabolism and is also closely linked to androgen metabolism. The more The further the disease has progressed, the lower the CRYM level in the tumor tissue. "Low CRYM values ​​are associated with a poor prognosis. CRYM also blocks the absorption of choline by cells, which is an important component in the formation of cell membranes. Since tumors are characterized by rapid cell division and therefore require many new cell membranes, CRYM can inhibit tumor growth by hindering the uptake of choline.

As a result, CRYM counteracts the growth of prostate tumors in two ways, making it an important anti-tumor control mechanism that opens up new treatment options. The study concludes that activation of CRYM could be used as a means of blocking tumor growth. The results also suggest a similar form of interaction between cancer cells and T3 in other hormonal cancers.

Source:

medical university Vienna

Journal reference:

O. Aksoy et al. (2020) Thyroid and androgen receptor signals are antagonized by μ-crystallin in prostate cancer. International Journal of Cancer. doi.org/10.1002/ijc.33332.

Comments are closed.